MX362912B - Péptidos ube2t y vacunas que incluyen los mismos. - Google Patents
Péptidos ube2t y vacunas que incluyen los mismos.Info
- Publication number
- MX362912B MX362912B MX2015003017A MX2015003017A MX362912B MX 362912 B MX362912 B MX 362912B MX 2015003017 A MX2015003017 A MX 2015003017A MX 2015003017 A MX2015003017 A MX 2015003017A MX 362912 B MX362912 B MX 362912B
- Authority
- MX
- Mexico
- Prior art keywords
- ube2t
- methods
- peptides
- ctls
- inducing
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 8
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 8
- 229960005486 vaccine Drugs 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- 101000837581 Homo sapiens Ubiquitin-conjugating enzyme E2 T Proteins 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 102100028705 Ubiquitin-conjugating enzyme E2 T Human genes 0.000 abstract 3
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 3
- 230000001939 inductive effect Effects 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000005809 anti-tumor immunity Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940023041 peptide vaccine Drugs 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 230000002980 postoperative effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
- C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
- C12Y603/02019—Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1114—T cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Abstract
Se describen vacunas de péptidos contra el cáncer se describen en la presente. En particular, péptidos epitópicos derivados de UBE2T que provocan CTLs se proporcionan. Células aisladas que presentan antígeno con inducibilidad CTL y CTLs que eligen como blanco tales péptidos, así como los métodos para inducir la célula que presenta antígeno, o CTL también se proporcionan. La presente invención además proporciona composiciones farmacéuticas que contienen dichos péptidos epitópicos derivados de UBE2T o polinucleótidos que codifican los polipéptidos como ingredientes activos. Más aún, la presente invención proporciona métodos para el tratamiento y/o profilaxis de (es decir, prevenir) cánceres (tumores), y/o la prevención de una recurrencia postoperativa de los mismos, así como los métodos para inducir CTLs, métodos para inducir inmunidad anti tumores, usando los péptidos epitópicos derivados de UBE2T, polinucleótidos que codifican los péptidos, o células que presentan antígeno que presentan los péptidos, o las composiciones farmacéuticas de la presente invención.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261699550P | 2012-09-11 | 2012-09-11 | |
| PCT/JP2013/005321 WO2014041784A1 (en) | 2012-09-11 | 2013-09-09 | Ube2t peptides and vaccines containing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015003017A MX2015003017A (es) | 2015-06-10 |
| MX362912B true MX362912B (es) | 2019-02-22 |
Family
ID=50277926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015003017A MX362912B (es) | 2012-09-11 | 2013-09-09 | Péptidos ube2t y vacunas que incluyen los mismos. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10092634B2 (es) |
| EP (1) | EP2895600B1 (es) |
| JP (1) | JP6283861B2 (es) |
| KR (1) | KR102110873B1 (es) |
| CN (2) | CN107881158B (es) |
| AU (1) | AU2013317194B2 (es) |
| BR (1) | BR112015004349B1 (es) |
| CA (1) | CA2873155C (es) |
| DK (1) | DK2895600T3 (es) |
| ES (1) | ES2784862T3 (es) |
| HK (1) | HK1212730A1 (es) |
| IL (1) | IL236690B (es) |
| MX (1) | MX362912B (es) |
| PL (1) | PL2895600T3 (es) |
| RU (1) | RU2663350C2 (es) |
| SG (2) | SG10201701866QA (es) |
| TW (1) | TWI632162B (es) |
| WO (1) | WO2014041784A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6715004B2 (ja) | 2015-12-25 | 2020-07-01 | 宏 半田 | 免疫賦活化剤およびその製造方法 |
| ES2913268T3 (es) | 2017-01-25 | 2022-06-01 | Ose Immunotherapeutics | Método para fabricar una emulsión estable para la administración de péptidos |
| AU2018346765A1 (en) * | 2017-10-06 | 2020-04-16 | Oncotherapy Science, Inc. | Screening of T lymphocytes for cancer-specific antigens |
| KR102322832B1 (ko) * | 2019-04-22 | 2021-11-12 | 한국과학기술연구원 | 인간 백혈구 항원 a24:02 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도 |
| CN113679829B (zh) | 2020-05-18 | 2024-01-02 | 北京繁易纳维科技有限公司 | 一种预防癌症术后复发的肿瘤疫苗及其制备方法和应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| US5922687A (en) | 1995-05-04 | 1999-07-13 | Board Of Trustees Of The Leland Stanford Junior University | Intracellular delivery of nucleic acids using pressure |
| WO1998004720A1 (en) | 1996-07-26 | 1998-02-05 | Sloan-Kettering Institute For Cancer Research | Method and reagents for genetic immunization |
| ID27788A (id) | 1998-06-25 | 2001-04-26 | Kyogo Itoh Cs | Peptida-peptida antigen tumor yang diperoleh dari siklofilin b |
| PL200772B1 (pl) * | 1998-07-14 | 2009-02-27 | Corixa Corp | Izolowany polipeptyd, fuzja białkowa oraz ich zastosowanie, izolowany epitop komórki T, wektor ekspresyjny, komórka gospodarza, sposób stymulowania i/lub namnażania komórek T, izolowana populacja komórek T, kompozycja i jej zastosowanie oraz izolowane komórki T |
| TR200100936T2 (tr) | 1998-10-05 | 2001-08-21 | Pharmexa A/S | Terapötik aşılama |
| US6468546B1 (en) | 1998-12-17 | 2002-10-22 | Corixa Corporation | Compositions and methods for therapy and diagnosis of ovarian cancer |
| ATE389668T1 (de) | 2000-07-31 | 2008-04-15 | Greenpeptide Co Ltd | Tumorantigen |
| CN1898563B (zh) | 2003-09-24 | 2011-11-23 | 肿瘤疗法科学股份有限公司 | 诊断乳腺癌的方法 |
| US20070202109A1 (en) | 2003-09-24 | 2007-08-30 | Oncotherapy Science, Inc. | Method Of Diagnosing Breast Cancer |
| WO2008102906A1 (en) | 2007-02-20 | 2008-08-28 | Oncotherapy Science, Inc. | Hspc-hrpc transition genes |
| TWI610939B (zh) | 2007-02-21 | 2018-01-11 | 腫瘤療法 科學股份有限公司 | 表現腫瘤相關抗原之癌症的胜肽疫苗 |
| TW200908998A (en) | 2007-06-27 | 2009-03-01 | Oncotherapy Science Inc | Compositions and methods of treating cancer |
| US8323659B2 (en) | 2008-09-18 | 2012-12-04 | Keio University | Method for diagnosing and/or treating tumor |
| TWI500932B (zh) | 2008-12-05 | 2015-09-21 | Oncotherapy Science Inc | Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗 |
| RU2011130796A (ru) | 2008-12-24 | 2013-01-27 | Онкотерапи Сайенс, Инк. | Пептиды c1orf59 и содержащие их вакцины |
| TW201102081A (en) | 2009-05-11 | 2011-01-16 | Oncotherapy Science Inc | TTK peptides and vaccines including the same |
| TW201216982A (en) | 2010-10-21 | 2012-05-01 | Oncotherapy Science Inc | WDHD1 peptides and vaccines including the same |
| TW201300423A (zh) | 2010-10-21 | 2013-01-01 | Oncotherapy Science Inc | Ｃ１８ｏｒｆ５４胜肽與含此胜肽之疫苗 |
| AU2011336019B2 (en) | 2010-12-02 | 2016-07-07 | Oncotherapy Science, Inc. | TOMM34 peptides and vaccines including the same |
-
2013
- 2013-09-09 RU RU2015113436A patent/RU2663350C2/ru active
- 2013-09-09 AU AU2013317194A patent/AU2013317194B2/en active Active
- 2013-09-09 CA CA2873155A patent/CA2873155C/en active Active
- 2013-09-09 BR BR112015004349-6A patent/BR112015004349B1/pt active IP Right Grant
- 2013-09-09 KR KR1020147031506A patent/KR102110873B1/ko active IP Right Grant
- 2013-09-09 PL PL13837757T patent/PL2895600T3/pl unknown
- 2013-09-09 CN CN201711214045.9A patent/CN107881158B/zh active Active
- 2013-09-09 ES ES13837757T patent/ES2784862T3/es active Active
- 2013-09-09 JP JP2015530559A patent/JP6283861B2/ja active Active
- 2013-09-09 EP EP13837757.7A patent/EP2895600B1/en active Active
- 2013-09-09 MX MX2015003017A patent/MX362912B/es active IP Right Grant
- 2013-09-09 SG SG10201701866QA patent/SG10201701866QA/en unknown
- 2013-09-09 SG SG11201501761SA patent/SG11201501761SA/en unknown
- 2013-09-09 US US14/400,169 patent/US10092634B2/en active Active
- 2013-09-09 CN CN201380047407.3A patent/CN104619833B/zh active Active
- 2013-09-09 WO PCT/JP2013/005321 patent/WO2014041784A1/en active Application Filing
- 2013-09-09 DK DK13837757.7T patent/DK2895600T3/da active
- 2013-09-10 TW TW102132531A patent/TWI632162B/zh active
-
2015
- 2015-01-13 IL IL236690A patent/IL236690B/en active IP Right Grant
-
2016
- 2016-01-19 HK HK16100536.3A patent/HK1212730A1/zh unknown
-
2018
- 2018-08-31 US US16/120,102 patent/US11266729B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010014044A (es) | Peptidos de epitope cdca1 y vacunas que contienen los mismos. | |
| MX366365B (es) | Peptidos de kntc2 y vacunas que los contienen. | |
| PH12015502638A1 (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| WO2015061416A3 (en) | Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use | |
| PH12021551208A1 (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| GB201004575D0 (en) | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers | |
| MX362912B (es) | Péptidos ube2t y vacunas que incluyen los mismos. | |
| MX2011012013A (es) | Peptidos ttk y vacunas que incluyen los mismos. | |
| MX355759B (es) | Peptidos topk y vacunas que incluyen los mismos. | |
| MX2022006022A (es) | Peptido derivado de depdc1 y vacuna que lo contiene. | |
| EP4219525A3 (en) | Foxm1-derived peptide, and vaccine including same | |
| MX2011010191A (es) | Peptidos c6orf167 y vacunas que continen los mismos. | |
| SG10201900933YA (en) | Koc1-derived peptide and vaccine including same | |
| MX2015007015A (es) | Peptidos sema5b y vacunas que contienen los mismos. | |
| EP4282883A3 (en) | Cdca1-derived peptide and vaccine containing same | |
| BR112013005448A2 (pt) | peptídeos de ttll4 e vacinas contendo os mesmos. | |
| MX2021001357A (es) | Peptido derivado de cdca1 y vacuna que lo contiene. | |
| MX2012011666A (es) | Peptidos cluap1 y vacunas que incluyen los mismos. | |
| SG10201900835XA (en) | Urlc10-derived peptide and vaccine containing same | |
| MX2012006376A (es) | Peptidos mybl2 y vacunas que los contienen. | |
| MY194653A (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| MY194244A (en) | Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including Nsclc | |
| MY193910A (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| MY194241A (en) | Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including NSCLC | |
| EA202090821A1 (ru) | Новый метод иммунотерапии нескольких видов опухолей, таких как рак легкого, включая нмрл |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |